Search results for " Heart Failure"

showing 10 items of 154 documents

B-type natriuretic peptide trend predicts clinical significance of worsening renal function in acute heart failure

2019

Aims In acute heart failure (AHF), relationships between changes in B-type natriuretic peptide (BNP) and worsening renal function (WRF) and its prognostic implications have not been fully determined. We investigated the relationship between WRF and a decrease in BNP with in-hospital and 1-year mortality in AHF. Methods and results The Acute Kidney Injury NGAL Evaluation of Symptomatic heart faIlure Study (AKINESIS) was a prospective, international, multicentre study of AHF patients. Severe WRF (sWRF) was a sustained increase of >= 44.2 mu mol/L (0.5 mg/dL) or >= 50% in creatinine, non-severe WRF (nsWRF) was a non-sustained increase of >= 26.5 mu mol/L (0.3 mg/dL) or >= 50% in cr…

InotropeMaleTime Factorsmedicine.medical_treatmentWorsening renal function030204 cardiovascular system & hematologyKidneyKidney Function TestsRISK STRATIFICATIONchemistry.chemical_compound0302 clinical medicineAcute heart failure; B-type natriuretic peptide; Mortality; Worsening renal function; Acute Disease; Acute Kidney Injury; Aged; Biomarkers; Creatinine; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Function Tests; Male; Natriuretic Peptide Brain; Prognosis; Prospective Studies; Time FactorsNatriuretic Peptide BrainNatriuretic peptideProspective StudiesDISCHARGEAcute kidney injuryBrainAcute Kidney InjuryPrognosis3. Good healthDERIVATIONHOSPITALIZATIONCreatinineAcute DiseaseCardiologyDisease ProgressionFemaleCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsGlomerular Filtration RateVENOUS CONGESTIONmedicine.medical_specialtymedicine.drug_classRenal functionPRESSUREVALIDATION03 medical and health sciencesNatriuretic PeptideInternal medicinemedicineHumansRenal replacement therapycardiovascular diseasesAgedMechanical ventilationHeart FailureCreatininebusiness.industryMORTALITYAcute heart failuremedicine.diseasechemistryB-type natriuretic peptideHeart failurebusinessBiomarkersFollow-Up Studies
researchProduct

Decongestion discriminates risk for one-year mortality in patients with improving renal function in acute heart failure

2021

Aims Improving renal function (IRF) is paradoxically associated with worse outcomes in acute heart failure (AHF), but outcomes may differ based on response to decongestion. We explored if the relationship of IRF with mortality in hospitalized AHF patients differs based on successful decongestion.Methods and results We evaluated 760 AHF patients from AKINESIS for the relationship between IRF, change in B-type natriuretic peptide (BNP), and 1-year mortality. IRF was defined as a >= 20% increase in estimated glomerular filtration rate (eGFR) relative to admission. Adequate decongestion was defined as a >= 40% decrease in last measured BNP relative to admission. IRF occurred in 22% of pat…

InotropeMalemedicine.medical_specialtymedicine.drug_classRenal function030204 cardiovascular system & hematologyKidney03 medical and health sciences0302 clinical medicineKidney functionNatriuretic PeptideB&#8208Internal medicineNatriuretic Peptide BrainNatriuretic peptidemedicinetype natriuretic peptideHumansBlood urea nitrogenAgedHeart Failurebusiness.industryAcute heart failure; B-type natriuretic peptide; Congestion; Kidney function; Prognosis; Acute Disease; Aged; Biomarkers; Humans; Kidney; Male; Natriuretic Peptide Brain; Prognosis; Heart FailureHazard ratioBrainAcute heart failuremedicine.diseasePrognosisConfidence interval3. Good healthBlood pressureB-type natriuretic peptideHeart failureAcute DiseaseCardiologyCongestionCardiology and Cardiovascular MedicinebusinessBiomarkersEuropean Journal of Heart Failure
researchProduct

Do the current guidelines for heart failure diagnosis and treatment fit with clinical complexity?

2022

Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients’ evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophys…

Left ventricular ejection fractiontherapyacute heart failureheart failure left ventricular ejection fraction New York Heart Association classification acute heart failure chronic heart failure phenotypes pathophysiology therapyAcute heart failure; Chronic heart failure; Heart failure; Left ventricular ejection fraction; New York Heart Association classification; Pathophysiology; Phenotypes; TherapyRphenotypesAcute heart failureheart failureHeart failureleft ventricular ejection fractionGeneral MedicineNew York Heart Association classificationPathophysiologyChronic heart failurechronic heart failurePhenotypesMedicineTherapyacute heart failure; chronic heart failure; heart failure; left ventricular ejection fraction; new york heart association classification; pathophysiology; phenotypes; therapypathophysiology
researchProduct

PROTOCOLLO ECOGRAFICO DEL PAZIENTE CON SCOMPENSO CARDIACO: RISULTATI AGGIORNATI DELLO STUDIO MULTICENTRICO SIUMB ABCDE 2018-2022

2019

Lo scompenso cardiaco è una sindrome clinica caratterizzata da specifici segni e sintomi causati da anomalie cardiache di tipo strutturale e/o funzionale. La prevalenza dello scompenso cardiaco è di circa 1-2% nella popolazione adulta dei paesi industrializzati, aumenta fin oltre il 10% oltre i 70 anni ed è la maggiore causa di ospedalizzazione oltre che di disabilità. L’approccio ecografico al paziente con scompenso cardiaco è ad oggi pratica comune, sia per la valutazione della funzionalità cardiaca, sia per il monitoraggio dello stato di volemia che per la quantificazione del liquido interstiziale. Dal 2018 è in corso uno studio multicentrico italiano (“ABCDE”) patrocinato dalla SIUMB ch…

Lung ultrasound Internal medicine heart failure DopplerSettore MED/09 - Medicina Interna
researchProduct

The role of macrophage colony-stimulating factor in patients with acute myocardial infarction: a pilot study.

2011

We assessed whether macrophage colony-stimulating factor (M-CSF) levels are associated with left ventricular systolic dysfunction (LVSD) in patients with acute myocardial infarction (AMI). We studied 56 patients with AMI (mean age: 67 ± 12 years) and identified those with clinical (Killip class >II) or echocardiographic signs (ejection fraction ≤45%) of LVSD. We evaluated the established cardiovascular risk factors and measured several cardiovascular biomarkers, including M-CSF. Serum M-CSF concentrations (pg/mL) were significantly increased in patients with both clinical and echocardiographic signs of LVSD (460 ± 265 vs 290 ± 210, P = .0103 and 493 ± 299 vs 287 ± 174, P = .0028, respec…

Macrophage colony-stimulating factorMalemedicine.medical_specialtymacrophage colony-stimulating factor myocardial infarction heart failureMyocardial InfarctionPilot ProjectsLogistic regressionVentricular Dysfunction LeftPredictive Value of TestsInternal medicineMedicineHumansMyocardial infarctionKillip classAgedEjection fractionbusiness.industryMacrophage Colony-Stimulating FactorOdds ratiomedicine.diseaseConfidence intervalPredictive value of testsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Immunity, Inflammation and Heart Failure. Their Role on Cardiac Function and Iron Status

2019

Aims: Heart failure is a clinical syndrome characterized by subclinical systemic inflammation and immune system activation associated with iron deficiency. No data exist on the various activations of immune-mediated mechanisms of inflammation in heart failure patients with reduced/preserved ejection fraction. We aimed to (1) investigate possible differences in inflammatory parameters and oxidative stress, and (2) detect a different iron status between groups. Materials and Methods: We enrolled 50 consecutive Caucasian outpatients with heart failure. All patients underwent echocardiographic measurements, laboratory determinations, evaluation of iron status and Toll-like receptors, and NF-κB …

Male0301 basic medicineheart failureSystemic inflammationGastroenterologyVentricular Function LeftElectrocardiographychemistry.chemical_compound0302 clinical medicineiron deficiencyImmunology and Allergyejection fraction; heart failure; inflammation; iron deficiency; toll-like receptorejection fractionOriginal ResearchAged 80 and overEjection fractionbiologymedicine.diagnostic_testToll-Like ReceptorsIron deficiencyMiddle AgedHeart Function TestsSerum ironCytokinesFemaleDisease SusceptibilityInflammation Mediatorsmedicine.symptomlcsh:Immunologic diseases. AllergyCardiac function curvemedicine.medical_specialtyIronImmunology03 medical and health sciencesHepcidinsInternal medicinemedicineHumansAgedCreatininebusiness.industryImmunitymedicine.diseaseFerritinOxidative Stress030104 developmental biologychemistryinflammationHeart failurebiology.proteintoll-like receptorlcsh:RC581-607businessBiomarkers030215 immunology
researchProduct

Multiple hormonal and metabolic deficiency syndrome in chronic heart failure: rationale, design, and demographic characteristics of the T.O.S.CA. Reg…

2018

Recent evidence supports the concept that progression of chronic heart failure (CHF) depends upon an imbalance of catabolic forces over the anabolic drive. In this regard, multiple hormonal deficiency syndrome (MHDS) significantly has impacts upon CHF progression, and is associated with a worse clinical status and increased mortality. The T.O.S.CA. (Trattamento Ormonale nello Scompenso CArdiaco; Hormone Therapy in Heart Failure) Registry (clinicaltrial.gov = NCT02335801) tests the hypothesis that anabolic deficiencies reduce survival in a large population of mild-to-moderate CHF patients. The T.O.S.CA. Registry is a prospective multicenter observational study coordinated by “Federico II” Un…

MaleAnabolismmedicine.medical_treatment030204 cardiovascular system & hematologylaw.invention0302 clinical medicineRandomized controlled triallawClinical endpointMedicineDeficiency Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyTestosteroneAnabolic deficiency; Chronic heart failure; Heart failure metabolism; Multiple hormonal deficiency syndrome; Registry; Aged; Biomarkers; Chronic Disease; Deficiency Diseases; Disease Progression; Female; Heart Failure; Humans; Italy; Male; Metabolic Diseases; Middle Aged; Prospective Studies; Registries; Internal Medicine; Emergency MedicineMiddle AgedItalyEmergency MedicineDisease ProgressionFemaleHumanmedicine.medical_specialtyRegistryAnabolic deficiencyAnabolic deficiency Chronic heart failure Heart failure metabolism Multiple hormonal deficiency syndrome RegistrySocio-culturaleHeart failure metabolism03 medical and health sciencesMetabolic DiseasesInternal medicineInternal MedicineHumansAgedHeart Failurebusiness.industryMultiple hormonal deficiency syndromeSettore MED/13 - ENDOCRINOLOGIABiomarkermedicine.diseaseChronic heart failureMetabolic DiseaseProspective StudieHeart failureChronic DiseaseObservational studyHormone therapybusinessDeficiency DiseasesBiomarkersInternal and emergency medicine
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

12‐Month outcomes of transcatheter tricuspid valve repair with the PASCAL system for severe tricuspid regurgitation

2021

Objectives We investigated the durability of tricuspid regurgitation (TR) reduction and the clinical outcomes through 12 months after transcatheter tricuspid valve repair (TTVr) with the PASCAL Transcatheter Valve Repair System. Background TTVr has rapidly developed and demonstrated favorable acute outcomes, but longer follow-up data are needed. Methods Overall, 30 patients (age 77 ± 6 years; 57% female) received PASCAL implantation from September 2017 to May 2019 and completed a clinical follow-up at 12 months. Results The TR etiology was functional in 25 patients (83%), degenerative in three (10%), and mixed in two (7%). All patients had TR severe or greater (massive or torrential in 80%)…

MaleCardiac Catheterizationmedicine.medical_specialtyTime FactorsRegurgitation (circulation)030204 cardiovascular system & hematologytranscatheter tricuspid valve intervention PASCAL 12-month outcomes severe tricuspid regurgitation right-sided heart failure03 medical and health sciences0302 clinical medicinemedicineHumansEndocarditisRadiology Nuclear Medicine and imagingddc:610030212 general & internal medicineTRICUSPID VALVE REPAIRStrokeSurvival rateAgedAged 80 and overHeart Valve Prosthesis Implantationbusiness.industryPascal (unit)General Medicinemedicine.diseaseTricuspid Valve InsufficiencySurgeryTreatment OutcomeHeart failureEtiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicinebusinessCatheterization and Cardiovascular Interventions
researchProduct